CoChat

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

Open access
Avet-Loiseau, Hervé, Ludwig, Heinz, Landgren, Ola, Paiva, Bruno, Morris, Chris, Yang, Hui, Zhou, Kefei, Ro, Sunhee, Mateos, Maria-Victoria · 2020 · Clinical Lymphoma Myeloma and Leukemia
Cited by 134

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background Therapeutic advances have greatly extended survival times in patients with multiple myeloma, necessitating increasingly lengthy trials when using survival outcomes primary endpoints. A surrogate endpoint that can more rapidly predict survival could accelerate drug development. We conducted a meta-analysis to evaluate minimal residual disease (MRD) status as a valid PFS surrogate in newly diagnosed multiple myeloma (NDMM). Materials and Methods We searched abstracts in PubMed, The American Society of Hematology (ASH) and the European Hematology Association (EHA) for “myeloma”, “minimal residual disease”, and “clinical trial”. Because of the need to evaluate the treatment effect on MRD response, only randomized studies for subjects with NDMM were included. Details on the MRD-tested populations were required. Meta-analysis was performed by principles outlined at the 2013 FDA workshop on MRD in AML.1 For samples that were not measured for MRD and within the subset specified for MRD assessment, their MRD status was imputed from the samples that had known MRD status. Patients that were excluded from planned MRD assessment were considered MRD positive. Results Six randomized studies, representing 3283 patients and 2208 MRD samples, met analysis inclusion criteria. MRD-negativity rates ranged from 0.06 to 0.70. The treatment effect on the odds ratio (OR) for MRD-negative response strongly correlated with the hazard ratio (HR) for PFS with a coefficient of determination for the weighted regression line of 0.97. Our meta-analysis suggested that MRD status met both Prentice’s criteria for PFS surrogacy. Conclusions These results support the claim that MRD status can be used as a surrogate for PFS in NDMM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clml.2019.09.622

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Avet-Loiseau, H., Ludwig, H., Landgren, O., Paiva, B., Morris, C., Yang, H., Zhou, K., Ro, S., & Mateos, M.-V.
Venue
Clinical Lymphoma Myeloma and Leukemia
Publisher
Elsevier BV
Published
2020-01
Volume
20
Issue
1
Pages
e30-e37
ISSN
2152-2650 (ISSN-L)
OpenAlex
W2980015215
Cited by
134
References
13
FWCI
3.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.